Asset Details
Do you wish to reserve the book?
Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model
Do you wish to request the book?
Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model
2013
Overview
Aim： To investigate whether strontium ranelate （SR）, a new antiosteoporotic agent, could attenuate cartilage degeneration and sub- chondral bone remodeling in osteoarthritis （OA）. Methods： Medial meniscal tear （MMT） operation was performed in adult SD rats to induce OA. SR （625 or 1800 mg·kg^-1·d^-1） was administered via gavage for 3 or 6 weeks. After the animals were sacrificed, articular cartilage degeneration was evaluated using toluidine blue 0 staining, SOX9 immunohistochemistry and TUNEL assay. The changes in microarchitecture indices and tissue mineral density （TMD）, chemical composition （mineral-to-collagen ratio）, and intrinsic mechanical properties of the subchondral bones were measured using micro-CT scanning, confocal Raman microspectroscopy and nanoindentation testing, respectively. Results： The high-dose SR significantly attenuated cartilage matrix and chondrocyte loss at 6 weeks, and decreased chondrocyte apop- tosis, improved the expression of SOX9, a critical transcription factor responsible for the expression of anabolic genes type II collagen and aggrecan, at both 3 and 6 weeks. Meanwhile, the high-dose SR also significantly attenuated the subchondral bone remodeling at both 3 and 6 weeks, as shown by the improved microarchitecture indices, TMD, mineral-to-collagen ratio and intrinsic mechanical prop- erties. In contrast, the low-dose SR did not significantly change all the detection indices of cartilage and bone at both 3 and 6 weeks. Conclusion： The high-dose SR treatment can reduce articular cartilage degeneration and subchondral bone remodeling in the rat MMT model of OA.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Bone Density Conservation Agents - administration & dosage
/ Bone Density Conservation Agents - therapeutic use
/ Bone Remodeling - drug effects
/ Dose-Response Relationship, Drug
/ Male
/ Menisci, Tibial - drug effects
/ MMT模型
/ Original
/ Osteoarthritis - drug therapy
/ Rats
/ SD大鼠
/ SOX9 Transcription Factor - metabolism
/ Thiophenes - administration & dosage
/ Thiophenes - therapeutic use
/ TUNEL法
/ Vaccine
/ 共焦显微拉曼光谱
/ 关节软骨
/ 变性
/ 微体系结构
/ 骨关节炎
